Feb 26, 2024 / 12:00PM GMT
Martin Ãmark - Xbrane Biopharma AB - CEO
Hello, everybody, and welcome to our call in relation to the Q4 report 2023. My name is Martin. I'm the CEO of Extreme biopharma and today and I have the pleasure of having with me a few more members of our team to present the handle potential questions coming from all of you.
I have Anders Tullgren, Chairman of the Board; and Mats Thorén, Board member. As usual, I have our CFO, Anette Lindqvist, but now I also have our COO and Head of Biosimilars, Siavash Bashiri, as well as Anders Wallström, our Head of Manufacturing. But we will, as we usually do start with the formal presentation to go through the highlights of the quarter and 2023 and what we have ahead of us for 2024. And then we will have a Q&A session, Torsten first to look back at 2023. And I must say that despite them the financial difficulties we ended up in during the second half of the year. I am very proud of what we've been able to accomplish operationally and everybody who has been involved in development and manufacturing of pharmaceuticals and above all biological drugs know this. We
Q4 2023 Xbrane Biopharma AB Earnings Call Transcript
Feb 28, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers